Results 11 to 20 of about 3,103 (173)

The Epidemiology of HIV-1 Resistance to Two-Drug Regimens in Multicenter Cohort From Poland-A Cross-Sectional Study. [PDF]

Health Sci Rep
ABSTRACT Background and Aims Concerns about antiretroviral therapy failure are growing among people with HIV receiving two‐drug regimens, as these schemes include fewer active agents, while the prevalence of transmitted resistance in HIV‐1 continues to increase.
Załęski A, Lembas A, Osińska J, Dyda T, Suchacz M, Stempkowska-Rejek J, Orzechowska J, Wiercińska-Drapało A.   +7 more
europepmc   +2 more sources

Counterfactual estimation of efficacy against placebo for novel PrEP agents using external trial data: example of injectable cabotegravir and oral PrEP in women

Journal of the International AIDS Society, 2023
Introduction Multiple antiretroviral agents have demonstrated efficacy for human immunodeficiency virus (HIV) pre‐exposure prophylaxis (PrEP). As a result, clinical trials of novel agents have transitioned from placebo‐ to active‐controlled designs ...
Deborah Donnell, Fei Gao, James P. Hughes, Brett Hanscom, Lawrence Corey, Myron S. Cohen, Srilatha Edupuganti, Nyaradzo Mgodi, Helen Rees, Jared M. Baeten, Glenda Gray, Linda‐Gail Bekker, Mina Hosseinipour, Sinead Delany‐Moretlwe   +13 more
doaj   +1 more source

Promises and challenges: cabotegravir for preexposure prophylaxis

Current Opinion in HIV and AIDS, 2022
Purpose of review Tenofovir-based oral PrEP has been effective in reducing population-level HIV incidence in multiple settings, although disparities remain. Injectable cabotegravir-based PrEP is an alternative that may be attractive to individuals with adherence challenges or who do not desire to take a daily medication.
Spinelli, Matthew A, Grinsztejn, Beatriz, Landovitz, Raphael J   +2 more
openaire   +4 more sources

Safety and Pharmacokinetic Profiles of Long-Acting Injectable Antiretroviral Drugs for HIV-1 Pre-Exposure Prophylaxis: A Systematic Review and Meta-analysis of Randomized Trials

Frontiers in Pharmacology, 2021
Objectives: To investigate the safety and pharmacokinetic profiles of long-acting injectable pre-exposure prophylaxis (LAI PrEP), notably cabotegravir (CAB-LA) and rilpivirine (RPV-LA), for the prevention of human immunodeficiency virus-1 (HIV-1 ...
Gilbert Lazarus, Vincent Kharisma Wangsaputra, Christianto, Melva Louisa, Vivian Soetikno, Raph L. Hamers, Raph L. Hamers, Raph L. Hamers   +7 more
doaj   +1 more source

Long-Acting Cabotegravir for HIV/AIDS Prophylaxis

Biochemistry, 2021
The retrovirus HIV-1 is the etiological agent of the decades-long AIDS pandemic. Although vaccination is the most common preexposure route to prevent acquisition of viral disease, scalable efficacious vaccination strategies have yet to be developed for HIV-1.
Kathleen D. Engelman, Alan N. Engelman
openaire   +3 more sources

Securing accelerated access to long‐acting injectable cabotegravir for HIV prevention in low‐ and middle‐income countries

Journal of the International AIDS Society, 2023
Introduction Reductions in HIV acquisition have slowed, and the global community is significantly off track from global goals. Oral pre‐exposure prophylaxis (PrEP) alone cannot address the diverse needs of the millions of people at risk of HIV ...
Sarah Y. Jenkins, Danielle Resar, Zachary Panos, Alan Staple, Melynda Watkins, David Ripin, Carolyn Amole   +6 more
doaj   +1 more source

Shaping and coordinating the implementation science agenda for injectable cabotegravir for PrEP: the role of the Biomedical Prevention Implementation Collaborative (BioPIC)

Journal of the International AIDS Society, 2023
Introduction Data from two randomized controlled trials (RCTs) showed that injectable cabotegravir (CAB) for pre‐exposure prophylaxis (PrEP) was efficacious in reducing HIV acquisition.
Mitchell Warren, Wawira Nyagah, Catherine Verde Hashim, Michelle Rodolph, Robin Schaefer, Heather‐Marie A Schmidt, Rachel Baggaley   +6 more
doaj   +1 more source

Design and synthesis of cabotegravir derivatives bearing 1,2,3-triazole and evaluation of anti-liver cancer activity

Frontiers in Pharmacology, 2023
Based on the structure of the anti-HIV drug cabotegravir, we introduced 1,2,3-triazole groups with different substituents to obtain 19 cabotegravir derivatives and tested their activity against HepG2 cells.
Huaxia Xie, Longfei Mao, Gaolu Fan, Ziyuan Wu, Yimian Wang, Xixi Hou, Jiangang Wang, Huili Wang, Ling Liu, Sanqiang Li   +9 more
doaj   +1 more source

Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland

Pharmaceutics, 2022
SHCS#879 is an ongoing Switzerland-wide multicenter observational study conducted within the Swiss HIV Cohort Study (SHCS) for the prospective follow-up of people living with HIV (PLWH) receiving long-acting injectable cabotegravir-rilpivirine (LAI-CAB ...
Paul Thoueille, Susana Alves Saldanha, Fabian Schaller, Aline Munting, Matthias Cavassini, Dominique Braun, Huldrych F. Günthard, Katharina Kusejko, Bernard Surial, Hansjakob Furrer, Andri Rauch, Pilar Ustero, Alexandra Calmy, Marcel Stoeckle, Manuel Battegay, Catia Marzolini, Pascal Andre, Monia Guidi, Thierry Buclin, Laurent A. Decosterd, on behalf of the Swiss HIV Cohort Study   +20 more
doaj   +1 more source

Formulation and pharmacology of long-acting cabotegravir [PDF]

Current Opinion in HIV and AIDS, 2015
Long-acting cabotegravir may provide a novel therapeutic option for both the treatment and prevention of HIV-1 infection that does not necessitate adherence to a daily regimen. The present review will highlight the unique formulation properties and pharmacologic attributes of long-acting cabotegravir nanosuspension.Cabotegravir is a potent integrase ...
Trezza, Christine, Ford, Susan L., Spreen, William, Pan, Rennan, Piscitelli, Stephen   +4 more
openaire   +2 more sources